Navigation Links
Molecular biology of sleep apnea could lead to new treatments
Date:3/19/2008

PHILADELPHIA Researchers at the University of Pennsylvania School of Medicine have provided, for the first time, a detailed look at the molecular pathways underlying sleep apnea, which affects more than twelve million Americans, according to the National Institutes of Health. Sleep apnea is a condition characterized by temporary breathing interruptions during sleep, in which disruptions can occur dozens or even hundreds of times a night.

The team found that in an animal model of sleep apnea poorly folded proteins accumulate in one compartment of a muscle nerve cell, which, under certain conditions, tells a cell to heal itself or destroy itself. The findings appear in a recent issue of the Journal of Neuroscience.

Muscles relax as a normal part of sleep, causing the airway to close, explains senior author Sigrid C. Veasey, MD, Associate Professor of Medicine, at the Penn Center for Sleep. But in patients with sleep apnea, oxygen levels in cells drop too low, sending an arousal signal to wake by gasping for air. This happens all night long, so patients experience bad quality sleep. In addition to problems with sleepiness, subtle peripheral neural injury occurs.

In a mouse model of sleep apnea, the researchers found that motor neurons of the jaw and face had swollen endoplasmic reticula, the part of the cell where proteins get folded properly. They surmised that misfolded proteins accumulated as the endoplasmic reticula of mice were exposed to decreased oxygen and oxygen fluctuations during sleep over eight weeks. The involvement of the endoplasmic reticula has never been shown before in explaining the physiology of sleep apnea on a cellular level, says Veasey.

But how does this work? Sensor proteins sitting on the surface of the endoplasmic reticula get activated by poorly folded proteins within. The Penn group worked with one of those proteins, called PERK. When PERK gets activated, two things can happen: The cell can take a pathway to fix itself or one that leads to self destruction. The cell makes that decision based on its initial health.

If a patient has sleep apnea with healthy cells, the cells will take the fix-it path. Then good things happen; the cell activates another molecule called eIF-2alpha, which turns on helpful molecules like anti-oxidants that degrade the misfolded proteins, explains Veasey.

However if cells are unhealthy to begin with, the PERK pathway can also turn on molecules that cause the cell to turn on itself and activate apoptosis or cell death. In this event, we predict that patients with sleep apnea may lose motor neurons, notes Veasey. Eventually sleep apnea could continue to worsen since the few remaining neurons are already stressed when gasping for air during sleep.

A drug called salubrinal does keep the eIF-2alpha path active, thereby preventing vulnerable cells from going down the cell-death path. But salubrinal is a double-edged sword: Just the right amount keeps the cell happy, but too much can shut down all protein synthesis, a highly toxic outcome.

The research team is now working on how to ramp up the eIF-2alpha path with changes in the mouse diet. This paper shows which pathways are important for treating sleep apnea, but well need to come up with therapies other than salubrinal, says Veasey. Ultimately if we can do healthy things that protect the endoplasmic reticula of cells, then sleep apnea wont be such an insult, not only to motor neurons, but neurons involved in cognition and alertness.


'/>"/>

Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. A new molecular zip code, and a new drug target for Huntingtons disease
2. New knock-out gene model provides molecular clues to breast cancer
3. Molecular probe paints cancer cells in living animals, Stanford researchers find
4. Story ideas from molecular & cellular proteomics
5. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
6. SNM seeks novel approaches to molecular imaging to showcase at annual meeting
7. Molecular fingerprint of breast-cancer drug resistance can predict response to treatment
8. Molecular profiling can accurately predict survival in colon cancer patients
9. Xceed Molecular Names Fran Tuttle to Its Board of Trustees
10. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
11. Xceed Molecular Launches Ziplex(R) Automated Gene-Expression System at the Association for Molecular Pathology, Booth 84/85
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... The SeniorCare ... the 2017 Forecast —on Thursday, February 23, 2017, at 1:00 PM ET. A recording ... is part of the Interactive Webinar Series. , If you want to find out ...
(Date:2/22/2017)... Marlton, NJ (PRWEB) , ... February 22, 2017 ... ... has served military veterans who suffer from combat-related PTSD. , Established in 1977, ... During the Vietnam-era, the challenges of military returning to civilian life were evident ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... itself - the Vector™ Series Multi-Cook Oven offers up to four ovens in ... exclusive Structured Air Technology™ for unmatched evenness in cooking. Alto-Shaam has partnered with ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins ... Clinic in Durant, Oklahoma, on Feb. 21. , The celebration began with a ... members, clinic employees, the construction team and tribal leadership. , Choctaw Nation ...
(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... SEATTLE , Feb. 22, 2017 ... translational development of novel immune modulating therapies, today ... the a9a10 nicotinic acetylcholine receptor (nAChR), demonstrates robust ... preclinical pain models. The study also establishes the ... the treatment of chronic pain. The findings were ...
(Date:2/22/2017)... , Feb. 22, 2017  Soligenix, Inc. ... Company), a late-stage biopharmaceutical company focused on developing ... there is an unmet medical need, announced today ... been granted a European patent for the treatment ... and methods of treatment of skin conditions, complements ...
(Date:2/21/2017)... -- IBM (NYSE: IBM ) Research has today announced new ... the eye,s retina. The Melbourne based ... recognize abnormalities in retina images, which could in the future ... of patients who may be at risk of eye diseases ... the developed world. The research began in ...
Breaking Medicine Technology: